Yes, epcoritamab, marketed under the brand name Epkinly, is FDA approved. It received approval on May 19, 2023.

Beremagene geperpavec topical, marketed under the brand name Vyjuvek, is an FDA-approved medication for treating wounds caused by dystrophic epidermolysis bullosa (DEB).

Perfluorohexyloctane ophthalmic, marketed under the brand name Miebo, is an FDA-approved medication for treating dry eye disease.

Fezolinetant, sold under the brand name Veozah, was approved by the FDA on May 12, 2023.

The FDA approved Arexvy on May 3, 2023. It is the first respiratory syncytial virus (RSV) vaccine approved for older adults.

The FDA approved VOWST on April 26, 2023, for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI.

Yes, Tofersen, marketed under the brand name Qalsody, received FDA approval on April 25, 2023.

Omidubicel, marketed under the brand name Omisirge, is FDA approved. The FDA granted approval on April 17, 2023.

Vilobelimab, marketed under the brand name Gohibic, has been authorized by the FDA for emergency use but has not yet received full FDA approval for the treatment of COVID-19.

It received approval on March 24, 2023, for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in individuals aged 12 years and older.

Retifanlimab, marketed under the brand name Zynyz, was approved by the FDA on March 22, 2023.

Rezafungin, marketed under the brand name Rezzayo, was approved by the FDA on March 22, 2023.